2019년 외부감사인 선임 보고

외부감사인 선임 공고

 

 

당사의 제12~14(2019.1.1~2021.12.31) 사업연도에 대한

외부감사인이 선임되었는바,

"주식회사 등의 외부감사에 관한 법률 제10조 및 제12"에 의거,

아래와 같이 공고합니다.

 


== 아 래 ==


   1. 외부 감사인 우리회계법인

   2. 감사대상기간 12~14기까지

       3개사업연도(2019.1.1~2021.12.31)

   3. 선임일 및 외부감사계약일 : 2019년 2월 14일 / 2019년 2월 14

 

 


     2019 년 월 14 

    대전시 유성구 유성대로 1689번길 70, 연구2동 2

       주식회사 파멥신

        대표이사 유진산

PharmAbcine Inc. is a bio venture specialized in R&D of antibody treatment in the clinical stage and currently possesses core technologies
such as potent antibody development technology using potent non-immune scFv phage display library, new-generation double target antibody
production technology, and antibody production technology using cancer stem cell library. Since we were established in 2008 we have been
devoted to developing new cancer antibody drugs and laying a foundation for TTAC-0001 and PMC-001. We will constantly develop pipelines
for sustainable growth with a vision to release a new global blockbuster bio drug by 2020 and become a global bioengineering company.

Core Technology

◑ Core Technology Potent antibody development technology using potent non-immune scFv phage display library,
◑ Double target antibody production technology
◑ Antibody evaluation technology using patients' cancer stem cell library
◑ ADC-based antibody therapy development technology 
◑ Immune anti-cancer antibody drug development technology
◑ Cell treatment development technology based on CAR-T/NK 

PR Video

Stock Price Information